Introduction {#s1}
============

Diabetes is a major cause of mortality and morbidity worldwide, and it has become an important public health problem in China ([@B1], [@B2]). National surveys indicate that the prevalence of diabetes increased dramatically among Chinese adults during the past three decades. The rising prevalence of diabetes highlights the urgent need for aggressive strategies aimed at the prevention and control of diabetes ([@B3], [@B4]). Type 2 diabetes mellitus (T2DM) is the most prevalent type of diabetes around the world. Substantial evidence demonstrates that T2DM is a complex metabolic disease triggered by lifestyle, environmental and genetic factors ([@B5]--[@B8]).

The paraoxonase 2 (PON2) gene encodes a member of the PON multigene family, which includes two other known members sharing approximately 65% sequence similarity at the amino acid level, PON1 and PON3, located adjacent to each other on the chromosome 7q21.3--22.1 in humans ([@B9]). PON1 and PON3 are primarily expressed in the liver while PON2 is ubiquitously expressed in many different mammalian tissues ([@B10]). The *PON2* gene contains eight introns and nine exons. It is polymorphic and several common single nucleotide polymorphisms (SNP) have been identified thus far. Currently, genetic variations in *PON2* gene may be associated with a number of disorders, such as cardiovascular disease and T2DM ([@B11]--[@B14]).

In the previous genetic epidemiologic studies, the association between the Ser311Cys (rs6954345/rs7493) and Ala148Gly (rs11545942/rs12026) polymorphisms in *PON2* gene and the risk in developing T2DM has increased the focus on the Chinese population. In Qu\'s study, *PON2* Ser311Cys gene polymorphism was found to be significantly associated with an increased risk of T2DM in a northern Chinese population ([@B15]). In 2014, Xu and Dai also revealed that *PON2* 311Cys allele could increase the T2DM risk in the Qinghai population ([@B16]). In contrast, Sun reported an opposite result that the *PON2* 311Ser contributed to the development of T2DM in another northern Chinese population, with the frequency of *PON2* 311Ser allele being significantly higher in T2DM patients than the control groups ([@B17]). In addition, Xu et al. ([@B18]) failed to find an association between *PON2* Ser311Cys gene variation and T2DM in an Anhui population in 2007 and Sun et al. ([@B19]) also observed a similar effect in another northern population.

It is crucial to address this inconsistency among the currently published studies. In the present study, a comprehensive meta-analysis was conducted by pooling all qualified individual data from case-control studies to make a precise conclusion on the association between *PON2* Ser311Cys and Ala148Gly gene polymorphisms and the risk of developing T2DM in the Chinese population.

Methods {#s2}
=======

This study was performed in accordance with the guidelines of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement ([@B20]).

Publication search and inclusion criteria
-----------------------------------------

The following electronic databases PubMed, Embase, Wanfang Data, and China National Knowledge Infrastructure (CNKI) were searched for all case-control studies published up to August 2017 on the association of *PON2* Ser311Cys and Ala148Gly gene polymorphisms and the risk of developing T2DM in the Chinese population. The search was performed in the databases in English and Chinese with proper keywords: paraoxonase 2 gene ("paraoxonase 2," "*PON2*") or variations (e.g., "Single Nucleotide Polymorphism," "SNP," "polymorphism," "Mutation," "variation," "variant") in combination with T2DM (e.g., "Type 2 Diabetes Mellitus," "Diabetes Mellitus, Type 2," "Noninsulin Dependent Diabetes Mellitus," "Diabetes Mellitus, Noninsulin Dependent"). In addition, the references from relevant reviews or primary studies were hand searched to identify additional studies.

Two investigators independently reviewed all studies for eligibility. The inclusion criteria were as follows: (a) study investigating the associations between Ser311Cys (rs6954345/rs7493) and Ala148Gly (rs11545942/rs12026) in *PON2* gene and the risk of developing T2DM. (b) case-control studies, regardless of sample size. (c) studies providing the numbers of *PON2* genotypes or alleles in case and control subjects. (d) the distribution of genotypes in the control groups met the Hardy-Weinberg equilibrium (HWE, *P* \> 0.05). Disagreement between two investigators regarding the eligibility of any study was resolved by the consensus of a third reviewer.

Data extraction
---------------

Data extraction was independently performed by two reviewers. A consensus on all items of data extraction was reached by both reviewers. The following items were extracted from each study: the first author\'s name, publication year, region of the study, mean age and gender distribution of the participants, number of genotypes, distribution of alleles, sample size in case, and control groups.

Statistical analysis
--------------------

In our meta-analysis, 5 genetic models as the allelic (C vs. S of *PON2* Ser311Cys gene polymorphism; G vs. A of *PON2* Ala148Gly gene polymorphism), homozygous (CC vs. SS of *PON2* Ser311Cys gene polymorphism; GG vs. AA of *PON2* Ala148Gly gene polymorphism), dominant (CC+SC vs. SS of *PON2* Ser311Cys gene polymorphism; GG+AG vs. AA of *PON2* Ala148Gly gene polymorphism), heterozygous (SC vs. SS of *PON2* Ser311Cys gene polymorphism; AG vs. AA of *PON2* Ala148Gly gene polymorphism) and recessive (CC vs. SS+SC of *PON2* Ser311Cys gene polymorphism; GG vs. AA+AG of *PON2* Ala148Gly gene polymorphism) were performed.

The odds ratio (OR) and their corresponding 95% confidence interval (CI) were employed to assess the association of *PON2* Ser311Cys and Ala148Gly gene polymorphisms with the risk of T2DM. The pooled OR was evaluated by *Z*-test with significance set at *P*-value \< 0.05. The test for heterogeneity between studies was performed using the Chi-square based *Q*-test and Higgins *I*^2^ index (ranging from 0 to 100%) ([@B21]). If there was significant heterogeneity between studies, the random-effect model using DerSimonian and Laird method was used. Otherwise, the fixed-effect model (Mantel--Haenszel method) was adopted for the meta-analysis. Galbraith plot was used to explore sources of between-study heterogeneity. The potential publication bias was evaluated by Begg\'s funnel plot and Egger\'s linear regression test ([@B22], [@B23]). The statistical analyses were performed by using Stata 12.0 software (StataCorp, College Station, TX, USA).

Results {#s3}
=======

Summary of included studies
---------------------------

In the initial screening, 208 articles were identified and 60 articles were excluded due to duplicate publication. Based on the inclusion criteria for meta-analysis the association of *PON2* Ser311Cys and Arg148Gly polymorphisms with T2DM, 89 articles were excluded after screening the abstract and title, and 44 articles were excluded after screening the full-texts. Finally, 15 articles were included. One article investigated the two polymorphisms in the same population. As a result, a total of 12 eligible studies were included for meta-analysis of *PON2* Ser311Cys polymorphism ([@B15]--[@B19], [@B24]--[@B30]), and 4 studies for meta-analysis of *PON2* Arg148Gly polymorphism ([@B17], [@B31]--[@B33]). Figure [1](#F1){ref-type="fig"} illustrated the selection process. Characteristics of the 16 studies on *PON2* Ser311Cys and Arg148Gly polymorphisms and risk of developing T2DM susceptibility were summarized in Table [1](#T1){ref-type="table"}. In addition, the HWE-P value in the control group in all studies was also listed in Table [1](#T1){ref-type="table"}.

![Flow diagram of the selection process of research studies The terms "*n*" in the boxes represent the number of corresponding studies.](fendo-09-00495-g0001){#F1}

###### 

Characteristics of included studies of the association of *PON2* Ser311Cys and Arg148Gly genetic polymorphisms with type 2 diabetes mellitus.

  **References**             **Area[^a^](#TN1){ref-type="table-fn"}**   **Male/Female**   **Age(years)**   **Genotyping method**   **Sample size[^b^](#TN2){ref-type="table-fn"}**   **Genotypes or alleles (case/control)**[^**c**^](#TN3){ref-type="table-fn"}   **HWE-*P*[^d^](#TN4){ref-type="table-fn"}**                                                   
  -------------------------- ------------------------------------------ ----------------- ---------------- ----------------------- ------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------- --------- --------- ------- --------- --------- -------
  ***PON2*** **Ser311Cys**                                                                                                                                                                                                                                                                                                                                       
  Wang et al. ([@B24])       Guangdong                                  50/55             64/53            57.4 ± 10.8             47.2 ± 11.9                                       PCR-RFLP                                                                      105/117                                       78/85     25/30     2/2     181/200   29/34     0.726
  Wang and Chang ([@B25])    Beijing                                    24/12             29/9             64.8 ± 11.9             70.8 ± 10.8                                       PCR-RFLP                                                                      36/38                                         12/13     19/17     5/8     43/43     29/33     0.581
  Fu and Zhang ([@B26])      Henan                                      NA                NA               59.9 ± 7.0              61.9 ± 6.8                                        PCR-RFLP                                                                      47/40                                         17/14     24/17     6/9     58/45     36/35     0.388
  Shi et al. ([@B27])        Gansu                                      14/12             18/12            54.0 ± 12.0             53.0 ± 4.0                                        PCR-RFLP                                                                      26/30                                         10/11     13/13     3/6     33/35     19/25     0.552
  Jiang et al. ([@B28])      Shanxi                                     20/22             21/24            54.9 ± 10.6             48.5 ± 13.1                                       TDI-FP                                                                        42/45                                         15/23     16/16     11/6    46/62     38/28     0.253
  Sun et al. ([@B17])        Jilin                                      92/85             50/47            64.5 ± 10.3             62.4 ± 10.9                                       PCR-RFLP                                                                      167/97                                        102/32    55/39     10/26   259/103   75/91     0.058
  Xu et al. ([@B18])         Anhui                                      166/161           90/94            60.7 ± 8.9              55.1 ± 9.2                                        PCR-RFLP                                                                      327/184                                       205/123   108/52    14/9    518/298   136/70    0.262
  Qu et al. ([@B15])         Mixed                                      204/230           245/288          49.7 ± 13.2             48.4 ± 8.2                                        PCR-RFLP                                                                      434/533                                       276/385   151/133   7/15    703/903   165/163   0.396
  Chen et al. ([@B29])       Fujian                                     50/47             55/50            59.9 ± 10.6             58.7 ± 5.7                                        PCR-RFLP                                                                      97/105                                        71/71     21/28     5/6     163/170   31/40     0.166
  Sun et al. ([@B19])        Heilongjiang                               79/131            181/138          NA                      NA                                                PCR-RFLP                                                                      210/319                                       134/200   69/95     3/8     337/495   75/111    0.406
  Xu and Dai ([@B16])        Qinghai                                    NA                63/25            NA                      72.0 ± 9.6                                        PCR-RFLP                                                                      18/88                                         5/59      7/25      6/4     17/143    19/33     0.526
  Ma et al. ([@B30])         Shanxi                                     NA                NA               NA                      NA                                                PCR-RFLP                                                                      65/70                                         23/34     32/30     10/6    78/98     52/42     0.864
  ***PON2*** **Arg148Gly**                                                                                                                                                                                                                                                                                                                                       
  Hao et al. ([@B31])        Fujian                                     44/34             20/23            53.4 ± 3.2              53.4 ± 3.6                                        PCR-RFLP                                                                      78/43                                         51/30     24/12     3/1     126/72    30/14     0.876
  Feng et al. ([@B32])       Beijing                                    65/67             67/65            53.2 ± 10.0             53.7 ± 11.2                                       PCR-RFLP                                                                      132/132                                       81/78     42/40     5/6     204/196   52/52     0.766
  Wang and Hu ([@B33])       Beijing                                    58/47             51/49            59.27±*NA*              59.35±*NA*                                        PCR-RFLP                                                                      105/100                                       74/70     27/24     4/6     175/164   35/36     0.061
  Sun et al. ([@B17])        Jilin                                      92/85             50/47            64.5 ± 10.3             62.4 ± 10.9                                       PCR-RFLP                                                                      154/97                                        89/71     54/21     11/5    232/163   76/31     0.056

*HWE, Hardy--Weinberg equilibrium; NA, not available PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; TDI---FP, template-directed dye-terminator incorporated with fluorescence polarization detection (TDI-FP)*.

*Mixed means Beijing and Heinongjiang*.

*Sample size means the case/control groups*.

*For the PON2 Ser311Cys, 11: SS, 12: SC, 22: CC; For the PON2 Arg148Gly, 11: AA, 12:AG, 22: GG*.

*P value for Hardy--Weinberg equilibrium test in controls*.

Pooled analyses
---------------

The main results of this meta-analysis for the association between *PON2* Ser311Cys polymorphism and risk of developing T2DM are shown in Table [2](#T2){ref-type="table"}. There was no significant association between the *PON2* Ser311Cys polymorphism and T2DM risk under all genetic models: allelic (OR = 1.06, 95% CI = 0.77--1.45; *P* = 0.721), heterozygous (OR = 1.13, 95% CI = 0.87--1.45; *P* = 0.362), dominant (OR = 1.10, 95% CI = 0.80--1.51; *P* = 0.562), recessive (OR = 0.87, 95% CI = 0.48--1.58; *P* = 0.648), homozygous (OR = 0.94, 95% CI = 0.47--1.89; *P* = 0.865) (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

###### 

Summary of meta-analysis of association between *PON2* Ser311Cys genetic polymorphism and risk of type 2 diabetes mellitus in the Chinese population.

  **Genetic model**            **Pooled analysis**   **Tests of heterogeneity**   **Tests of publication bias**                                       
  ---------------------------- --------------------- ---------------------------- ------------------------------- ---- --- ---------- ------- ------- -------
  Allelic genetic model        1.06(0.77--1.45)      0.36                         0.721                           12   R   \< 0.001   82.50   0.824   0.837
  Recessive genetic model      0.87(0.48--1.58)      0.46                         0.648                           12   R   \< 0.001   69.30   0.133   0.451
  Dominant genetic model       1.10(0.80--1.51)      0.58                         0.562                           12   R   \< 0.001   72.10   0.913   0.537
  Homozygous genetic model     0.94(0.47--1.89)      0.17                         0.865                           12   R   \< 0.001   75.20   0.126   0.631
  Heterozygous genetic model   1.13(0.87--1.45)      0.91                         0.362                           12   R   0.025      49.90   0.659   0.631

*CI, confidence interval; N, the number of the studies in the meta-analysis; OR, odds ratio; R, random-effects model; T2DM, type 2 diabetes mellitus; Allelic genetic model, C vs. S, Recessive genetic model, CC vs. SC + CC, Dominant genetic model, CC + SC vs. SS, Homozygous genetic model, CC vs. SS, Heterozygous genetic model, SC vs. SS*.

![Forest plot of the meta-analysis for association between *PON2* Ser311Cys polymorphism and type 2 diabetes risk under the allelic **(A)**, homozygous **(B)**, recessive **(C)**, heterozygous **(D)**, and dominant **(E)** genetic model.](fendo-09-00495-g0002){#F2}

The main results of this meta-analysis in the association between *PON2* Arg148Gly polymorphism and risk of developing T2DM are listed in Table [3](#T3){ref-type="table"}. No significant association between the *PON2* Arg148Gly polymorphism and T2DM risk was also found in all genetic models: allelic (OR = 1.17, 95% CI = 0.91--1.50; *P* = 0.218), heterozygous (OR = 1.28, 95% CI = 0.94--1.74; *P* = 0.117), dominant (OR = 1.25, 95% CI = 0.93--1.67; *P* = 0.142), recessive (OR = 0.99, 95% CI = 0.52--1.88; *P* = 0.973), homozygous (OR = 1.08, 95% CI = 0.57--2.07; *P* = 0.808) (Figure [3](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}).

###### 

Summary of meta-analysis of association between *PON2* Arg148Gly genetic polymorphism and risk of type 2 diabetes mellitus in the Chinese population.

  **Genetic model**            **Pooled analysis**   **Tests of heterogeneity**                           
  ---------------------------- --------------------- ---------------------------- ------- --- --- ------- -------
  Allelic genetic model        1.17(0.91--1.50)      1.23                         0.218   4   F   0.220   32.00
  Recessive genetic model      0.99(0.52--1.88)      0.03                         0.973   4   F   0.744   0.00
  Dominant genetic model       1.25(0.93--1.67)      1.47                         0.142   4   F   0.236   29.30
  Homozygous genetic model     1.08(0.57--2.07)      0.24                         0.808   4   F   0.616   0.00
  Heterozygous genetic model   1.28(0.94--1.74)      1.57                         0.117   4   F   0.315   15.40

*CI, confidence interval; N, the number of the studies in the meta-analysis; OR, odds ratio; R, random-effects model; T2DM, type 2 diabetes mellitus; Allelic genetic model, G vs. A, Recessive genetic model, GG vs. AG + AA, Dominant genetic model, GG + AG vs. AA, Homozygous genetic model, GG vs. AA, Heterozygous genetic model, AG vs. AA*.

![Forest plot of the meta-analysis for association between *PON2* Ala148Gly polymorphism and type 2 diabetes risk under the allelic **(A)**, homozygous **(B)**, recessive **(C)**, heterozygous **(D)**, and dominant **(E)** genetic model.](fendo-09-00495-g0003){#F3}

Sources of heterogeneity
------------------------

The results of the heterogeneity analysis in *PON2* Ser311Cys polymorphism are summarized in Table [2](#T2){ref-type="table"}. There was significant between-study heterogeneity under all genetic models (allelic: *I*^2^ = 82.50%, *P*~heterogeneity~ \< 0.001; recessive: *I*^2^ = 69.30%, *P*~heterogeneity~ \< 0.001; dominant: *I*^2^ = 72.10%, *P*~heterogeneity~ \< 0.001; homozygous: *I*^2^ = 75.20%, *P*~heterogeneity~ \< 0.001; heterozygous: *I*^2^ = 49.90%, *P*~heterogeneity~ = 0.025). By contrast, as is shown in Table [3](#T3){ref-type="table"}, there was no heterogeneity in the meta-analysis in *PON2* Arg148Gly polymorphism under all five genetic models (allelic: *I*^2^ = 32.00%, *P*~heterogeneity~ = 0.220; recessive: *I*^2^ = 0%, *P*~heterogeneity~ = 0.744; dominant: *I*^2^ = 29.30%, *P*~heterogeneity~ = 0.236; homozygous: *I*^2^ = 0%, *P*~heterogeneity~ = 0.616; heterozygous: *I*^2^ = 15.40%, *P*~heterogeneity~ = 0.315).

Galbraith plot was performed to detect whether there were outliers which could be the potential sources of between-study heterogeneity in the meta-analysis of *PON2* Ser311Cys polymorphism. The analysis showed that the studies conducted by Sun et al. ([@B17]) and Xu and Dai ([@B16]) were the outliers under the allelic (Figure [4A](#F4){ref-type="fig"}), homozygous (Figure [4B](#F4){ref-type="fig"}) and recessive (Figure [4C](#F4){ref-type="fig"}) genetic models. For the heterozygous (Figure [4D](#F4){ref-type="fig"}) and dominant (Figure [4E](#F4){ref-type="fig"}) genetic models, Galbraith plot analysis indicated that Sun YD and Qu YC\'s study were the outliers. In addition, Xu HN\'s study may also contribute to the significant heterogeneity under a dominant genetic model.

![Galbraith plot of the meta-analysis for association between *PON2* Ser311Cys polymorphism and type 2 diabetes risk under the allelic **(A)**, homozygous **(B)**, recessive **(C)**, heterozygous **(D)**, and dominant **(E)** genetic model.](fendo-09-00495-g0004){#F4}

After exclusion of these outliers studies from the meta-analysis, the recalculated summary ORs were still insignificant but the between-study heterogeneity significantly decreased in all genetic models: allelic (*I*^2^ = 14%, *P*~heterogeneity~ = 0.314), homozygous (*I*^2^ = 0%, *P*~heterogeneity~ = 0.475), recessive (*I*^2^ = 0%, *P*~heterogeneity~ = 0.512), heterozygous (*I*^2^ = 0%, *P*~heterogeneity~ = 0.706) and dominant (*I*^2^ = 0%, *P*~heterogeneity~ = 0.721) (Table [4](#T4){ref-type="table"}).

###### 

Summary of meta-analysis of association between *PON2* Ser311Cys genetic polymorphism and risk of type 2 diabetes mellitus in the Chinese population after omitting the outliers.

  **Genetic model**            **Pooled analysis**   **Tests of heterogeneity**   **References**                            
  ---------------------------- --------------------- ---------------------------- ---------------- ---- --- ------- ------- --------------------------------------------------------------
  Allelic genetic model        1.12(0.98--1.28)      1.73                         0.084            10   F   0.314   14.00   Sun et al. ([@B17]); Xu and Dai ([@B16])
  Recessive genetic model      0.86(0.61--1.22)      0.85                         0.397            10   F   0.512   0.00    Sun et al. ([@B17]); Xu and Dai ([@B16])
  Dominant genetic model       1.10(0.91--1.34)      0.97                         0.332            9    F   0.721   0.00    Sun et al. ([@B17]); Qu et al. ([@B15]); Xu and Dai ([@B16])
  Homozygous genetic model     0.94(0.65--1.36)      0.32                         0.751            10   F   0.475   0.00    Sun et al. ([@B17]); Xu and Dai ([@B16])
  Heterozygous genetic model   1.15(0.95--1.41)      1.40                         0.161            10   F   0.706   0.00    Sun et al. ([@B17]); Qu et al. ([@B15])

*CI, confidence interval; F, fixed-effects model; N, the number of the studies in the meta-analysis; OR, odds ratio; T2DM, type 2 diabetes mellitus; Allelic genetic model, C vs. S, Recessive genetic model, CC vs. SC + CC, Dominant genetic model, CC + SC vs. SS, Homozygous genetic model, CC vs. SS, Heterozygous genetic model, SC vs. SS*.

Publication bias analyses
-------------------------

The publication bias in the meta-analysis of *PON2* Ser311Cys polymorphism was assessed by Begg\'s funnel plot (Figure [5](#F5){ref-type="fig"}, Table [2](#T2){ref-type="table"}) and Egger\'s test (Table [2](#T2){ref-type="table"}). The Begg\'s funnel plot appeared symmetric in all genetic models, with *P* = 0.824 for allelic genetic model (Figure [5A](#F5){ref-type="fig"}); *P* = 0.126 for homozygous genetic model (Figure [5B](#F5){ref-type="fig"}); *P* = 0.133 for recessive genetic model (Figure [5C](#F5){ref-type="fig"}); *P* = 0.659 for heterozygous genetic model (Figure [5D](#F5){ref-type="fig"}); *P* = 0.913 for dominant genetic model (Figure [5E](#F5){ref-type="fig"}), suggesting no evidence of publication bias.

![Begg\'s funnel plot of the meta-analysis for association between *PON2* Ser311Cys polymorphism and type 2 diabetes risk under the allelic **(A)**, homozygous **(B)**, recessive **(C)**, heterozygous **(D)**, and dominant **(E)** genetic model.](fendo-09-00495-g0005){#F5}

Moreover, no evidence of publication bias was also detected by Egger\'s test (*P* = 0.837 for allelic genetic model; *P* = 0.451 for recessive genetic model; *P* = 0.537 for dominant genetic model; *P* = 0.631 for homozygous genetic model; *P* = 0.631 for heterozygous genetic model).

Discussion {#s4}
==========

T2DM is a silent progressive polygenic disease and associated with a number of genetic factors. The role of *PON2* gene in the glycemic control and risk of developing T2DM may be attributed to the widespread tissue expression of PON2, especially the expression in the pancreas. In addition, the expression in the cardiac and skeletal muscle suggests that PON2 could play important roles in the peripheral utilization of glucose ([@B34]). Consequently, a large number of researchers have focused on the associations of the *PON2* Ser311Cys and Ala148Gly variations with T2DM risk in the Chinese population. However, the genetic association between the two *PON2* SNPs and the risk of developing 2DM was uncertain owing to conflicting results generated by various independent case-control studies.

To our knowledge, this is the first comprehensive meta-analysis to assess the genetic association between *PON2* Ser311Cys and Ala148Gly polymorphisms and T2DM risk in the Chinese population. Our findings demonstrated that *PON2* Ser311Cys and Ala148Gly genetic polymorphisms were not significantly associated with the risk of developing of T2DM in the Chinese population. The pooled OR and 95% CI were examined with five genetic models including the allelic, homozygous, heterozygous, recessive and dominant, and consistently no significant effects of *PON2* Ser311Cys and Ala148Gly genotypes on T2DM risk were found.

Interestingly, both *PON2* Ser311Cys and Ala148Gly polymorphisms were found not to be associated with the susceptibility of T2DM. The two polymorphisms, Ser311Cys and Ala148Gly, were located at the exon nine and exon five of the *PON2* gene, respectively. By checking the two SNPs (Ser311Cys/rs6954345/rs7493 and Arg148Gly/rs11545942/rs12026) information available for Chinese population in the 1000 genomics database (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>), we found that the minor allele frequency of *PON2* Ser311Cys and Ala148Gly were the same each other: 0.20 in Southern Han Chinese and 0.18 in Beijing Han Chinese. In addition, Dasgupta et al. reported that *PON2* Ser311Cys and Ala148Gly polymorphisms were in strong linkage disequilibrium (LD) with each other (*r*^2^ = 0.81) ([@B35]). Therefore, strong LD between *PON2* Ser311Cys and Ala148Gly polymorphisms may explain the consistent findings existed in the two *PON2* genetic polymorphisms.

In the meta-analysis of *PON2* Ser311Cys polymorphism, there was substantial between-study heterogeneity under all five genetic models. Therefore, the Galbraith plot was employed to identify the outliers that could be the possible sources of between-study heterogeneity. The Galbraith plot analyses indicated that the studies conducted by Sun et al. ([@B17]), Xu and Dai ([@B16]), and Qu et al. ([@B15]) were the outliers and could largely account for the significant heterogeneity when all eligible studies were pooled into our meta-analysis. Xu HN\'s study had the largest OR while Sun YD\'s study had the smallest OR among the included studies. After omitting these outlier studies, the *I*^2^ values immediately decreased to 14% in an allelic genetic model and 0% in other four genetic models, and the *P*-values of the *Q*-test in all genetic models were \>0.1. Moreover, the pooled ORs remained statistically insignificant in all genetic models, which demonstrated that our meta-analysis results were stable and reliable.

One previous meta-analysis assessed the association of *PON2* Ser311Cys and Ala148Gly gene polymorphisms with diabetic nephropathy and retinopathy in Caucasian populations ([@B36]). However, only three studies included PON2 Ser311Cys and two studies included Ala148Gly in the meta-analysis. The results showed these two *PON2* genetic polymorphisms were not associated with diabetic nephropathy and retinopathy in Caucasians. In addition, numerous meta-analyses have been conducted to determine the association of *PON2* Ser311Cys and Ala148Gly gene polymorphisms with the risk of developing other diseases, such as coronary heart disease ([@B37]--[@B39]), ischemic stroke ([@B40], [@B41]) and Alzheimer Disease ([@B42]). This current meta-analysis only focused on the association of *PON2* Ser311Cys and Ala148Gly gene polymorphisms and the risk of developing T2DM.

Our study has some limitations. First, some of the included studies were based on small sample size, which may have resulted in a decreased power to detect a significant difference in the distribution of genotypes or alleles between cases and controls. Second, the pooled OR is based on the crude OR in the original studies. Because we could not obtain enough raw data from individual studies, the pooled data were not adjusted by potential confounding factors such as gender, age, smoking status, body mass index and waist-hip ratio. Third, T2DM is a polygenic hereditary disorder. The current study only focused on the role of *PON2* genetic polymorphisms in the susceptibility to T2DM. Other susceptibility genes such as *PON1* and *PON3* gene may interact with *PON2* gene by gene-to-gene effect for T2DM ([@B34], [@B43]). Fourth, various environmental factors may be involved in the T2DM risk, the effect of gene-to-environment interactions should be taken into account. For example, synergistic effects between the *PON2* Ala148Gly polymorphism and obesity were found in the risk of T2DM ([@B32]). Finally, the current meta-analysis was based on data from candidate gene association studies because the genome-wide association studies (GWAS) data was not collected. Nevertheless, there is no evidence of publication bias assessed by Begg\'s funnel plot and Egger\'s test in the meta-analysis.

In conclusion, our meta-analysis confirmed that *PON2* Ser311Cys and Ala148Gly gene polymorphisms did not have a significant association with the risk of developing T2DM in the Chinese population. A well-designed study, with consideration of gene-to-gene and gene-to-environment interactions, should be conducted in the future.
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